Impact of new treatment options for hepatitis c virus infection in liver transplantation

World Journal of Gastroenterology

Volumn 21, Issue 38, 2015, Pages 10760-10775

  Righi, Elda ^a   Londero, Angela ^a   Carnelutti, Alessia ^a   Baccarani, Umberto ^a   Bassetti, Matteo ^a  

^a SANTA MARIA DELLA MISERICORDIA UNIVERSITY HOSPITAL   (Italy)

Author keywords

Direct antiviral agents; Hepatitis C virus; Liver transplantation

Indexed keywords

ANTIVIRUS AGENT; BOCEPREVIR; DACLATASVIR; DASABUVIR; DIRECT ACTING ANTIVIRAL AGENT; INTERFERON; OMBITASVIR; PARITAPREVIR; RIBAVIRIN; RITONAVIR; SIMEPREVIR; SOFOSBUVIR; TELAPREVIR; UNCLASSIFIED DRUG; NUCLEIC ACID SYNTHESIS INHIBITOR; PROTEINASE INHIBITOR; VIRUS RNA;

ANTIVIRAL THERAPY; ARTICLE; GRAFT RECIPIENT; HEPATITIS C; HUMAN; HUMAN IMMUNODEFICIENCY VIRUS INFECTION; LIVER CIRRHOSIS; LIVER TRANSPLANTATION; MIXED INFECTION; MULTICENTER STUDY (TOPIC); NONHUMAN; OUTCOME ASSESSMENT; RECURRENT INFECTION; TREATMENT OUTCOME; BIOSYNTHESIS; COINFECTION; COMBINATION DRUG THERAPY; HEPATITIS C, CHRONIC; HIV INFECTIONS; POSTOPERATIVE CARE; PREOPERATIVE CARE; RECURRENT DISEASE; VIROLOGY;

ANTIVIRAL AGENTS; COINFECTION; DRUG THERAPY, COMBINATION; HEPATITIS C, CHRONIC; HIV INFECTIONS; HUMANS; LIVER CIRRHOSIS; LIVER TRANSPLANTATION; NUCLEIC ACID SYNTHESIS INHIBITORS; POSTOPERATIVE CARE; PREOPERATIVE CARE; PROTEASE INHIBITORS; RECURRENCE; RNA, VIRAL;

EID: 84944096301     PISSN: 10079327     EISSN: 22192840     Source Type: Journal    
DOI: 10.3748/wjg.v21.i38.10760     Document Type: Article

References (146)

1. Global Burden Of Hepatitis C Working Group. Global burden of disease (GBD) for hepatitis C. J Clin Pharmacol 2004; 44: 20-29 [PMID: 14681338 DOI: 10.1177/0091270003258669]
2. Lavanchy D. The global burden of hepatitis C. Liver Int 2009; 29 Suppl 1: 74-81 [PMID: 19207969 DOI: 10.1111/j.1478-3231.2008.01934.x]
3. Rodger AJ, Roberts S, Lanigan A, Bowden S, Brown T, Crofts N. Assessment of long-term outcomes of community-acquired hepatitis C infection in a cohort with sera stored from 1971 to 1975. Hepatology 2000; 32: 582-587 [PMID: 10960453 DOI: 10.1053/jhep.2000.9714]
4. Perz JF, Armstrong GL, Farrington LA, Hutin YJ, Bell BP. The contributions of hepatitis B virus and hepatitis C virus infections to cirrhosis and primary liver cancer worldwide. J Hepatol 2006; 45: 529-538 [PMID: 16879891 DOI: 10.1016/j.jhep.2006.05.013]
5. Fattovich G, Giustina G, Degos F, Tremolada F, Diodati G, Almasio P, Nevens F, Solinas A, Mura D, Brouwer JT, Thomas H, Njapoum C, Casarin C, Bonetti P, Fuschi P, Basho J, Tocco A, Bhalla A, Galassini R, Noventa F, Schalm SW, Realdi G. Morbidity and mortality in compensated cirrhosis type C: a retrospective follow-up study of 384 patients. Gastroenterology 1997; 112: 463-472 [PMID: 9024300 DOI: 10.1053/gast.1997.v112.pm9024300]
6. Khan MH, Farrell GC, Byth K, Lin R, Weltman M, George J, Samarasinghe D, Kench J, Kaba S, Crewe E, Liddle C. Which patients with hepatitis C develop liver complications? Hepatology 2000; 31: 513-520 [PMID: 10655279 DOI: 10.1002/hep.510310236]
7. Szabó E, Lotz G, Páska C, Kiss A, Schaff Z. Viral hepatitis: new data on hepatitis C infection. Pathol Oncol Res 2003; 9: 215-221 [PMID: 14688826 DOI: 10.1007/BF02893380]
8. Biggins SW, Bambha KM, Terrault NA, Inadomi J, Shiboski S, Dodge JL, Gralla J, Rosen HR, Roberts JP. Projected future increase in aging hepatitis C virus-infected liver transplant candidates: a potential effect of hepatocellular carcinoma. Liver Transpl 2012; 18: 1471-1478 [PMID: 23008049 DOI: 10.1002/lt. 23551]
9. Adam R, McMaster P, O'Grady JG, Castaing D, Klempnauer JL, Jamieson N, Neuhaus P, Lerut J, Salizzoni M, Pollard S, Muhlbacher F, Rogiers X, Garcia Valdecasas JC, Berenguer J, Jaeck D, Moreno Gonzalez E. Evolution of liver transplantation in Europe: report of the European Liver Transplant Registry. Liver Transpl 2003; 9: 1231-1243 [PMID: 14625822 DOI: 10.1016/j.lts.2003.09.018]
10. Terrault N. Liver transplantation in the setting of chronic HCV. Best Pract Res Clin Gastroenterol 2012; 26: 531-548 [PMID: 23199510 DOI: 10.1016/j.bpg.2012.09.010]
11. Verna EC, Saxena V, Burton JR, O'Leary JG, Dodge JL, Stravitz RT, Levitsky J, Trotter JF, Everson GT, Brown RS, Terrault NA. Telaprevir-and Boceprevir-based Triple Therapy for Hepatitis C in Liver Transplant Recipients With Advanced Recurrent Disease: A Multicenter Study. Transplantation 2015; 99: 1644-1651 [PMID: 25715116 DOI: 10.1097/tp.0000000000000629]
12. AASLD and IDSA Guidelines. Recommendations for Testing Managing and Treating Hepatitis C. When and in whom to initiate HCV Therapy. Accessed April 2, 2015. Available from: URL: http://www.hcvguidelines.org/
13. Manns MP, Pockros PJ, Norkrans G, Smith CI, Morgan TR, Häussinger D, Shiffman ML, Hadziyannis SJ, Schmidt WN, Jacobson IM, Bárcena R, Schiff ER, Shaikh OS, Bacon B, Marcellin P, Deng W, Esteban-Mur R, Poynard T, Pedicone LD, Brass CA, Albrecht JK, Gordon SC. Long-term clearance of hepatitis C virus following interferon α-2b or peginterferon α-2b, alone or in combination with ribavirin. J Viral Hepat 2013; 20: 524-529 [PMID: 23808990 DOI: 10.1111/jvh.12074]
14. Backus LI, Boothroyd DB, Phillips BR, Belperio P, Halloran J, Mole LA. A sustained virologic response reduces risk of all-cause mortality in patients with hepatitis C. Clin Gastroenterol Hepatol 2011; 9: 509-516.e1 [PMID: 21397729 DOI: 10.1016/j.cgh.2011.03.004]
15. Dienstag JL, Ghany MG, Morgan TR, Di Bisceglie AM, Bonkovsky HL, Kim HY, Seeff LB, Szabo G, Wright EC, Sterling RK, Everson GT, Lindsay KL, Lee WM, Lok AS, Morishima C, Stoddard AM, Everhart JE. A prospective study of the rate of progression in compensated, histologically advanced chronic hepatitis C. Hepatology 2011; 54: 396-405 [PMID: 21520194 DOI: 10.1002/hep.24370]
16. European Association for Study of Liver. EASL Recommendations on Treatment of Hepatitis C 2015. J Hepatol 2015; 63: 199-236 [PMID: 25911336 DOI: 10.1016/j.jhep.2015.03.025]
17. Fried MW, Shiffman ML, Reddy KR, Smith C, Marinos G, Gonçales FL, Häussinger D, Diago M, Carosi G, Dhumeaux D, Craxi A, Lin A, Hoffman J, Yu J. Peginterferon alfa-2a plus ribavirin for chronic hepatitis C virus infection. N Engl J Med 2002; 347: 975-982 [PMID: 12324553 DOI: 10.1056/NEJMoa020047]
18. Manns MP, McHutchison JG, Gordon SC, Rustgi VK, Shiffman M, Reindollar R, Goodman ZD, Koury K, Ling M, Albrecht JK. Peginterferon alfa-2b plus ribavirin compared with interferon alfa-2b plus ribavirin for initial treatment of chronic hepatitis C: a randomised trial. Lancet 2001; 358: 958-965 [PMID: 11583749 DOI: 10.1016/S0140-6736(01)06102-5]
19. Hadziyannis SJ, Sette H, Morgan TR, Balan V, Diago M, Marcellin P, Ramadori G, Bodenheimer H, Bernstein D, Rizzetto M, Zeuzem S, Pockros PJ, Lin A, Ackrill AM. Peginterferon-alpha2a and ribavirin combination therapy in chronic hepatitis C: a randomized study of treatment duration and ribavirin dose. Ann Intern Med 2004; 140: 346-355 [PMID: 14996676 DOI: 10.7326/0 003-4819-140-5-200403020-00010]
20. Venkatraman S, Bogen SL, Arasappan A, Bennett F, Chen K, Jao E, Liu YT, Lovey R, Hendrata S, Huang Y, Pan W, Parekh T, Pinto P, Popov V, Pike R, Ruan S, Santhanam B, Vibulbhan B, Wu W, Yang W, Kong J, Liang X, Wong J, Liu R, Butkiewicz N, Chase R, Hart A, Agrawal S, Ingravallo P, Pichardo J, Kong R, Baroudy B, Malcolm B, Guo Z, Prongay A, Madison V, Broske L, Cui X, Cheng KC, Hsieh Y, Brisson JM, Prelusky D, Korfmacher W, White R, Bogdanowich-Knipp S, Pavlovsky A, Bradley P, Saksena AK, Ganguly A, Piwinski J, Girijavallabhan V, Njoroge FG. Discovery of (1R, 5S)-N-[3-amino-1-(cyclobutylmethyl)-2, 3-dioxopropyl]-3-[2(S)-[[[(1, 1-dimethylethyl)amino]carbonyl]amino]-3, 3-dimethyl-1-oxobutyl]-6, 6-dimethyl-3-azabicyclo[3.1.0]hexan-2(S)-carboxamide (SCH 503034), a selective, potent, orally bioavailable hepatitis C virus NS3 protease inhibitor: a potential therapeutic agent for the treatment of hepatitis C infection. J Med Chem 2006; 49: 6074-6086 [PMID: 17004721 DOI: 10.1021/jm060325b]
21. Lin C, Kwong AD, Perni RB. Discovery and development of VX-950, a novel, covalent, and reversible inhibitor of hepatitis C virus NS3.4A serine protease. Infect Disord Drug Targets 2006; 6: 3-16 [PMID: 16787300 DOI: 10.2174/187152606776056706]
22. Poordad F, McCone J, Bacon BR, Bruno S, Manns MP, Sulkowski MS, Jacobson IM, Reddy KR, Goodman ZD, Boparai N, DiNubile MJ, Sniukiene V, Brass CA, Albrecht JK, Bronowicki JP. Boceprevir for untreated chronic HCV genotype 1 infection. N Engl J Med 2011; 364: 1195-1206 [PMID: 21449783 DOI: 10.1056/NEJMoa1010494]
23. Bacon BR, Gordon SC, Lawitz E, Marcellin P, Vierling JM, Zeuzem S, Poordad F, Goodman ZD, Sings HL, Boparai N, Burroughs M, Brass CA, Albrecht JK, Esteban R. Boceprevir for previously treated chronic HCV genotype 1 infection. N Engl J Med 2011; 364: 1207-1217 [PMID: 21449784 DOI: 10.1056/NEJMoa1009482]
24. Jacobson IM, McHutchison JG, Dusheiko G, Di Bisceglie AM, Reddy KR, Bzowej NH, Marcellin P, Muir AJ, Ferenci P, Flisiak R, George J, Rizzetto M, Shouval D, Sola R, Terg RA, Yoshida EM, Adda N, Bengtsson L, Sankoh AJ, Kieffer TL, George S, Kauffman RS, Zeuzem S. Telaprevir for previously untreated chronic hepatitis C virus infection. N Engl J Med 2011; 364: 2405-2416 [PMID: 21696307 DOI: 10.1056/NEJMoa1012912]
25. Sherman KE, Flamm SL, Afdhal NH, Nelson DR, Sulkowski MS, Everson GT, Fried MW, Adler M, Reesink HW, Martin M, Sankoh AJ, Adda N, Kauffman RS, George S, Wright CI, Poordad F. Response-guided telaprevir combination treatment for hepatitis C virus infection. N Engl J Med 2011; 365: 1014-1024 [PMID: 21916639 DOI: 10.1056/NEJMoa1014463]
26. Ghany MG, Nelson DR, Strader DB, Thomas DL, Seeff LB. An update on treatment of genotype 1 chronic hepatitis C virus infection: 2011 practice guideline by the American Association for the Study of Liver Diseases. Hepatology 2011; 54: 1433-1444 [PMID: 21898493 DOI: 10.1002/hep.24641]
27. Vertex Pharmaceuticals discontinues Incivek. Canadian Treatment Action Council website. Accessed February 19, 2015. Available from: URL: http://www.ctac.ca/multimedia-press/treatmentaccessnews/vertex-pharmaceuticals-discontinues-incivek
28. Clinical Pharmacology [database online]. Accessed March 12, 2015. Tampa, FL: Gold Standard, Inc., 2014. Available from: URL: http://clinicalpharmacology-ip.com/default.aspx
29. FDA approves Sovaldi for chronic hepatitis C. FDA news release US food and Drug administration. Accessed December 6, 2013. Available from: URL: http://www.Fda.gov/newsevents/newsroom/pressannouncements/ucm377888.htm
30. Lam AM, Espiritu C, Bansal S, Micolochick Steuer HM, Niu C, Zennou V, Keilman M, Zhu Y, Lan S, Otto MJ, Furman PA. Genotype and subtype profiling of PSI-7977 as a nucleotide inhibitor of hepatitis C virus. Antimicrob Agents Chemother 2012; 56: 3359-3368 [PMID: 22430955 DOI: 10.1128/AAC.00054-12]
31. Sofa MJ, Bao D, Chang W, Du J, Nagarathnam D, Rachakonda S, Reddy PG, Ross BS, Wang P, Zhang HR, Bansal S, Espiritu C, Keilman M, Lam AM, Steuer HM, Niu C, Otto MJ, Furman PA. Discovery of a β-d-2'-deoxy-2'-α-fluoro-2'-β-C-methyluridine nucleotide prodrug (PSI-7977) for the treatment of hepatitis C virus. J Med Chem 2010; 53: 7202-7218 [PMID: 20845908 DOI: 10.1021/jm100863x]
32. Hsu CS. Sofosbuvir for previously untreated chronic hepatitis C infection. N Engl J Med 2013; 369: 678 [PMID: 23944317 DOI: 10.1056/NEJMoa1214853]
33. Lawitz E, Mangia A, Wyles D, Rodriguez-Torres M, Hassanein T, Gordon SC, Schultz M, Davis MN, Kayali Z, Reddy KR, Jacobson IM, Kowdley KV, Nyberg L, Subramanian GM, Hyland RH, Arterburn S, Jiang D, McNally J, Brainard D, Symonds WT, McHutchison JG, Sheikh AM, Younossi Z, Gane EJ. Sofosbuvir for previously untreated chronic hepatitis C infection. N Engl J Med 2013; 368: 1878-1887 [PMID: 23607594 DOI: 10.1056/NEJMoa1214854]
34. Mangia A, Piazzolla V. Overall efficacy and safety results of sofosbuvir-based therapies in phase II and III studies. Dig Liver Dis 2014; 46 Suppl 5: S179-S185 [PMID: 25458780 DOI: 10.1016/j.dld.2014.09.026]
35. Lawitz E, Rodriguez-Torres M, Cornpropst M. The effect of hepatic impairment on the safety, pharmacokinetics, and antiviral activity of GS-7977 in hepatitis C infected patients treated for seven days (abstr). J Hepatol 2012; 56 (Suppl 1): S445-S446 [DOI: 10.1016/S0168-8278(12)61142-8]
36. Lawitz E, Sulkowski MS, Ghalib R, Rodriguez-Torres M, Younossi ZM, Corregidor A, DeJesus E, Pearlman B, Rabinovitz M, Gitlin N, Lim JK, Pockros PJ, Scott JD, Fevery B, Lambrecht T, Ouwerkerk-Mahadevan S, Callewaert K, Symonds WT, Picchio G, Lindsay KL, Beumont M, Jacobson IM. Simeprevir plus sofosbuvir, with or without ribavirin, to treat chronic infection with hepatitis C virus genotype 1 in non-responders to pegylated interferon and ribavirin and treatment-naive patients: the COSMOS randomised study. Lancet 2014; 384: 1756-1765 [PMID: 25078309 DOI: 10.1016/S0140-6736(14)61036-9]
37. Afdhal N, Reddy KR, Nelson DR, Lawitz E, Gordon SC, Schiff E, Nahass R, Ghalib R, Gitlin N, Herring R, Lalezari J, Younes ZH, Pockros PJ, Di Bisceglie AM, Arora S, Subramanian GM, Zhu Y, Dvory-Sobol H, Yang JC, Pang PS, Symonds WT, McHutchison JG, Muir AJ, Sulkowski M, Kwo P. Ledipasvir and sofosbuvir for previously treated HCV genotype 1 infection. N Engl J Med 2014; 370: 1483-1493 [PMID: 24725238 DOI: 10.1056/NEJMoa1316366]
38. Kowdley KV, Gordon SC, Reddy KR, Rossaro L, Bernstein DE, Lawitz E, Shiffman ML, Schiff E, Ghalib R, Ryan M, Rustgi V, Chojkier M, Herring R, Di Bisceglie AM, Pockros PJ, Subramanian GM, An D, Svarovskaia E, Hyland RH, Pang PS, Symonds WT, McHutchison JG, Muir AJ, Pound D, Fried MW. Ledipasvir and sofosbuvir for 8 or 12 weeks for chronic HCV without cirrhosis. N Engl J Med 2014; 370: 1879-1888 [PMID: 24720702 DOI: 10.1056/NEJMoa1402355]
39. Poordad F, Hezode C, Trinh R, Kowdley KV, Zeuzem S, Agarwal K, Shiffman ML, Wedemeyer H, Berg T, Yoshida EM, Forns X, Lovell SS, Da Silva-Tillmann B, Collins CA, Campbell AL, Podsadecki T, Bernstein B. ABT-450/r-ombitasvir and dasabuvir with ribavirin for hepatitis C with cirrhosis. N Engl J Med 2014; 370: 1973-1982 [PMID: 24725237 DOI: 10.1056/NEJMoa1402869]
40. Andreone P, Colombo MG, Enejosa JV, Koksal I, Ferenci P, Maieron A, Müllhaupt B, Horsmans Y, Weiland O, Reesink HW, Rodrigues L, Hu YB, Podsadecki T, Bernstein B. ABT-450, ritonavir, ombitasvir, and dasabuvir achieves 97% and 100% sustained virologic response with or without ribavirin in treatment-experienced patients with HCV genotype 1b infection. Gastroenterology 2014; 147: 359-365.e1 [PMID: 24818763 DOI: 10.1053/j.gastro.2014.04.045]
41. Zeuzem S, Jacobson IM, Baykal T, Marinho RT, Poordad F, Bourlière M, Sulkowski MS, Wedemeyer H, Tam E, Desmond P, Jensen DM, Di Bisceglie AM, Varunok P, Hassanein T, Xiong J, Pilot-Matias T, DaSilva-Tillmann B, Larsen L, Podsadecki T, Bernstein B. Retreatment of HCV with ABT-450/r-ombitasvir and dasabuvir with ribavirin. N Engl J Med 2014; 370: 1604-1614 [PMID: 24720679 DOI: 10.1056/NEJMoa1401561]
42. Lawitz E, Poordad F, Brainard DM, Hyland RH, An D, Dvory-Sobol H, Symonds WT, McHutchison JG, Membreno FE. Sofosbuvir with peginterferon-ribavirin for 12 weeks in previously treated patients with hepatitis C genotype 2 or 3 and cirrhosis. Hepatology 2015; 61: 769-775 [PMID: 25322962 DOI: 10.1002/hep.27567]
43. Bourlière M, Bronowicki JP, de Ledinghen V, Hézode C, Zoulim F, Mathurin P, Tran A, Larrey DG, Ratziu V, Alric L, Hyland RH, Jiang D, Doehle B, Pang PS, Symonds WT, Subramanian GM, McHutchison JG, Marcellin P, Habersetzer F, Guyader D, Grangé JD, Loustaud-Ratti V, Serfaty L, Metivier S, Leroy V, Abergel A, Pol S. Ledipasvir-sofosbuvir with or without ribavirin to treat patients with HCV genotype 1 infection and cirrhosis non-responsive to previous protease-inhibitor therapy: a randomised, double-blind, phase 2 trial (SIRIUS). Lancet Infect Dis 2015; 15: 397-404 [PMID: 25773757 DOI: 10.1016/S1473-3099(15)70050-2]
44. Reddy KR, Bourlière M, Sulkowski M, Omata M, Zeuzem S, Feld JJ, Lawitz E, Marcellin P, Welzel TM, Hyland R, Ding X, Yang J, Knox S, Pang P, Dvory-Sobol H, Subramanian GM, Symonds W, McHutchison JG, Mangia A, Gane E, Mizokami M, Pol S, Afdhal N. Ledipasvir and sofosbuvir in patients with genotype 1 hepatitis C virus infection and compensated cirrhosis: An integrated safety and effcacy analysis. Hepatology 2015; 62: 79-86 [PMID: 25846144]
45. Bourliere M, Sulkowski MS, Omata M, Zeuzem S, Feld LL, Lawitz E, Marcellin P, Hyland RH, Ding X, Yang JC, Knox SJ, Pang PS, Subramanian M, Symonds WT, McHutchison JG, Mangia A, Gane EJ, Reddy KR, Mizokami M, Pol S, Afdhal NH. An Integrated Safety and Effcacy Analysis of >500 Patients with Compensated Cirrhosis Treated with Ledipasvir/Sofosbuvir with or without Ribavirin. 65th Annual Meeting of the American Association for the Study of Liver diseases, November 7-11, 2014; Boston, United States
46. Dieterich D, Bacon BR, Flamm SL, Kowdley K V, Milligan S, Tsai N, Yonoussi Z, Lawitz E. Evaluation of sofosbuvir and simeprevir-based regimens in the TRIO network: academic and community treatment of a real-world, heterogeneous population. 65th Annual Meeting of the American Association for the Study of Liver diseases, November 7-11, 2014; Boston, United States
47. Lawitz E, Gane E, Pearlman B, Tam E, Ghesquiere W, Guyader D, Alric L, Bronowicki JP, Lester L, Sievert W, Ghalib R, Balart L, Sund F, Lagging M, Dutko F, Shaughnessy M, Hwang P, Howe AY, Wahl J, Robertson M, Barr E, Haber B. Effcacy and safety of 12 weeks versus 18 weeks of treatment with grazoprevir (MK-5172) and elbasvir (MK-8742) with or without ribavirin for hepatitis C virus genotype 1 infection in previously untreated patients with cirrhosis and patients with previous null response with or without cirrhosis (C-WORTHY): a randomised, open-label phase 2 trial. Lancet 2015; 385: 1075-1086 [PMID: 25467591 DOI: 10.1016/S0140-6736(14)61795-5]
48. ClinicalTrials.gov. Safety and Effcacy of Grazoprevir (MK-5172) Elbasvir (MK-8742) in Participants with Chronic Hepatitis C and Chronic Kidney Disease (MK-5172-052) (C-SURFER). Identifer: NCT02092350
49. Muir AJ, Poordad F, Lalezari J, Everson G, Dore GJ, Herring R, Sheikh A, Kwo P, Hézode C, Pockros PJ, Tran A, Yozviak J, Reau N, Ramji A, Stuart K, Thompson AJ, Vierling J, Freilich B, Cooper J, Ghesquiere W, Yang R, McPhee F, Hughes EA, Swenson ES, Yin PD. Daclatasvir in combination with asunaprevir and beclabuvir for hepatitis C virus genotype 1 infection with compensated cirrhosis. JAMA 2015; 313: 1736-1744 [PMID: 25942724 DOI: 10.1001/jama.2015.3868]
50. Wiesner RH, Sorrell M, Villamil F. Report of the frst International Liver Transplantation Society expert panel consensus conference on liver transplantation and hepatitis C. Liver Transpl 2003; 9: S1-S9 [PMID: 14586888 DOI: 10.1053/jlts.2003.50268]
51. McCaughan GW, Zekry A. Pathogenesis of hepatitis C virus recurrence in the liver allograft. Liver Transpl 2002; 8: S7-S13 [PMID: 12362292 DOI: 10.1053/jlts.2002.35856]
52. Ballardini G, De Raffele E, Groff P, Bioulac-Sage P, Grassi A, Ghetti S, Susca M, Strazzabosco M, Bellusci R, Iemmolo RM, Grazi G, Zauli D, Cavallari A, Bianchi FB. Timing of reinfection and mechanisms of hepatocellular damage in transplanted hepatitis C virus-reinfected liver. Liver Transpl 2002; 8: 10-20 [PMID: 11799480 DOI: 10.1053/jlts.2002.30141]
53. Guerrero RB, Batts KP, Burgart LJ, Barrett SL, Germer JJ, Poterucha JJ, Wiesner RH, Charlton MR, Persing DH. Early detection of hepatitis C allograft reinfection after orthotopic liver transplantation: a molecular and histologic study. Mod Pathol 2000; 13: 229-237 [PMID: 10757333 DOI: 10.1038/modpathol.3880043]
54. Garcia-Retortillo M, Forns X, Feliu A, Moitinho E, Costa J, Navasa M, Rimola A, Rodes J. Hepatitis C virus kinetics during and immediately after liver transplantation. Hepatology 2002; 35: 680-687 [PMID: 11870384 DOI: 10.1053/jhep.2002.31773]
55. Rosen HR, Hinrichs DJ, Gretch DR, Koziel MJ, Chou S, Houghton M, Rabkin J, Corless CL, Bouwer HG. Association of multispecifc CD4(+) response to hepatitis C and severity of recurrence after liver transplantation. Gastroenterology 1999; 117: 926-932 [PMID: 10500076 DOI: 10.1016/S0016-5085(99)70352-5]
56. McCaughan GW, Zekry A. Effects of immunosuppression and organ transplantation on the natural history and immunopathogenesis of hepatitis C virus infection. Transpl Infect Dis 2000; 2: 166-185 [PMID: 11429029 DOI: 10.1034/j.1399-3062.2000.020403.x]
57. Gane EJ. The natural history of recurrent hepatitis C and what infuences this. Liver Transpl 2008; 14 Suppl 2: S36-S44 [PMID: 18825724 DOI: 10.1002/lt.21646]
58. Crespo G, Mariño Z, Navasa M, Forns X. Viral hepatitis in liver transplantation. Gastroenterology 2012; 142: 1373-1383.e1 [PMID: 22537446]
59. Tong MJ, el-Farra NS, Reikes AR, Co RL. Clinical outcomes after transfusion-associated hepatitis C. N Engl J Med 1995; 332: 1463-1466 [PMID: 7739682 DOI: 10.1056/NEJM199506013322202]
60. Féray C, Samuel D, Thiers V, Gigou M, Pichon F, Bismuth A, Reynes M, Maisonneuve P, Bismuth H, Bréchot C. Reinfection of liver graft by hepatitis C virus after liver transplantation. J Clin Invest 1992; 89: 1361-1365 [PMID: 1313453 DOI: 10.1172/JCI115723]
61. Reed A, Howard RJ, Fujita S, Foley DP, Langham MR, Schold JD, Nelson D, Soldevila-Pico C, Firpi R, Abdelmalek M, Morrelli G, Hemming AW. Liver retransplantation: a single-center outcome and financial analysis. Transplant Proc 2005; 37: 1161-1163 [PMID: 15848656 DOI: 10.1016/j.transproceed.2004.11.046]
62. Veldt BJ, Poterucha JJ, Watt KD, Wiesner RH, Hay JE, Rosen CB, Heimbach JK, Janssen HL, Charlton MR. Insulin resistance, serum adipokines and risk of fbrosis progression in patients transplanted for hepatitis C. Am J Transplant 2009; 9: 1406-1413 [PMID: 19459812 DOI: 10.1111/j.1600-6143.2009.02642.x]
63. Sabharwal S, Delgado-Borrego A, Chung RT. Extrahepatic hepatitis C virus after transplantation: diabetes and renal dysfunction. Liver Transpl 2008; 14 Suppl 2: S51-S57 [PMID: 18825714 DOI: 10.1002/lt.21613]
64. Hanouneh IA, Feldstein AE, McCullough AJ, Miller C, Aucejo F, Yerian L, Lopez R, Zein NN. The significance of metabolic syndrome in the setting of recurrent hepatitis C after liver transplantation. Liver Transpl 2008; 14: 1287-1293 [PMID: 18756451 DOI: 10.1002/lt.21524]
65. Forman LM, Lewis JD, Berlin JA, Feldman HI, Lucey MR. The association between hepatitis C infection and survival after orthotopic liver transplantation. Gastroenterology 2002; 122: 889-896 [PMID: 11910340 DOI: 10.1053/gast.2002.32418]
66. Charlton MR, Thompson A, Veldt BJ, Watt K, Tillmann H, Poterucha JJ, Heimbach JK, Goldstein D, McHutchison J. Interleukin-28B polymorphisms are associated with histological recurrence and treatment response following liver transplantation in patients with hepatitis C virus infection. Hepatology 2011; 53: 317-324 [PMID: 21254179 DOI: 10.1002/hep.24074]
67. Firpi RJ, Clark V, Soldevila-Pico C, Morelli G, Cabrera R, Levy C, Machicao VI, Chaoru C, Nelson DR. The natural history of hepatitis C cirrhosis after liver transplantation. Liver Transpl 2009; 15: 1063-1071 [PMID: 19718647 DOI: 10.1002/lt.21784]
68. Gallegos-Orozco JF, Yosephy A, Noble B, Aqel BA, Byrne TJ, Carey EJ, Douglas DD, Mulligan D, Moss A, de Petris G, Williams JW, Rakela J, Vargas HE. Natural history of post-liver transplantation hepatitis C: A review of factors that may infuence its course. Liver Transpl 2009; 15: 1872-1881 [PMID: 19938138 DOI: 10.1002/lt.21954]
69. Rosen HR, Gretch DR, Oehlke M, Flora KD, Benner KG, Rabkin JM, Corless CL. Timing and severity of initial hepatitis C recurrence as predictors of long-term liver allograft injury. Transplantation 1998; 65: 1178-1182 [PMID: 9603164 DOI: 10.1097/00007890-199805150-00006]
70. Charlton M, Seaberg E, Wiesner R, Everhart J, Zetterman R, Lake J, Detre K, Hoofnagle J. Predictors of patient and graft survival following liver transplantation for hepatitis C. Hepatology 1998; 28: 823-830 [PMID: 9731579 DOI: 10.1002/hep.510280333]
71. Bruno S, Shiffman ML, Roberts SK, Gane EJ, Messinger D, Hadziyannis SJ, Marcellin P. Effcacy and safety of peginterferon alfa-2a (40KD) plus ribavirin in hepatitis C patients with advanced fibrosis and cirrhosis. Hepatology 2010; 51: 388-397 [PMID: 19918980 DOI: 10.1002/hep.23340]
72. Everson GT, Hoefs JC, Seeff LB, Bonkovsky HL, Naishadham D, Shiffman ML, Kahn JA, Lok AS, Di Bisceglie AM, Lee WM, Dienstag JL, Ghany MG, Morishima C. Impact of disease severity on outcome of antiviral therapy for chronic hepatitis C: Lessons from the HALT-C trial. Hepatology 2006; 44: 1675-1684 [PMID: 17133499 DOI: 10.1002/hep.21440]
73. Van Thiel DH, Faruki H, Friedlander L, Fagiuoli S, Caraceni P, Molloy PJ, Kania RJ, Wright HI. Combination treatment of advanced HCV associated liver disease with interferon and G-CSF. Hepatogastroenterology 1995; 42: 907-912 [PMID: 8847044]
74. Everson GT, Trotter J, Forman L, Kugelmas M, Halprin A, Fey B, Ray C. Treatment of advanced hepatitis C with a low accelerating dosage regimen of antiviral therapy. Hepatology 2005; 42: 255-262 [PMID: 16025497 DOI: 10.1002/hep.20793]
75. Crippin JS, McCashland T, Terrault N, Sheiner P, Charlton MR. A pilot study of the tolerability and effcacy of antiviral therapy in hepatitis C virus-infected patients awaiting liver transplantation. Liver Transpl 2002; 8: 350-355 [PMID: 11965579 DOI: 10.1053/jlts.2002.31748]
76. Thomas RM, Brems JJ, Guzman-Hartman G, Yong S, Cavaliere P, Van Thiel DH. Infection with chronic hepatitis C virus and liver transplantation: a role for interferon therapy before transplantation. Liver Transpl 2003; 9: 905-915 [PMID: 12942451 DOI: 10.1053/jlts.2003.50166]
77. Carrión JA, Navasa M, García-Retortillo M, García-Pagan JC, Crespo G, Bruguera M, Bosch J, Forns X. Efficacy of antiviral therapy on hepatitis C recurrence after liver transplantation: a randomized controlled study. Gastroenterology 2007; 132: 1746-1756 [PMID: 17484872 DOI: 10.1053/j.gastro.2007.03.041]
78. Carrión JA, Martínez-Bauer E, Crespo G, Ramírez S, Pérez-del-Pulgar S, García-Valdecasas JC, Navasa M, Forns X. Antiviral therapy increases the risk of bacterial infections in HCV-infected cirrhotic patients awaiting liver transplantation: A retrospective study. J Hepatol 2009; 50: 719-728 [PMID: 19217183 DOI: 10.1016/j.jhep.2008.11.015]
79. Everson GT, Terrault NA, Lok AS, Rodrigo del R, Brown RS, Saab S, Shiffman ML, Al-Osaimi AM, Kulik LM, Gillespie BW, Everhart JE. A randomized controlled trial of pretransplant antiviral therapy to prevent recurrence of hepatitis C after liver transplantation. Hepatology 2013; 57: 1752-1762 [PMID: 22821361 DOI: 10.1002/hep.25976]
80. Osinusi A, Meissner EG, Lee YJ, Bon D, Heytens L, Nelson A, Sneller M, Kohli A, Barrett L, Proschan M, Herrmann E, Shivakumar B, Gu W, Kwan R, Teferi G, Talwani R, Silk R, Kotb C, Wroblewski S, Fishbein D, Dewar R, Highbarger H, Zhang X, Kleiner D, Wood BJ, Chavez J, Symonds WT, Subramanian M, McHutchison J, Polis MA, Fauci AS, Masur H, Kottilil S. Sofosbuvir and ribavirin for hepatitis C genotype 1 in patients with unfavorable treatment characteristics: a randomized clinical trial. JAMA 2013; 310: 804-811 [PMID: 23982366 DOI: 10.1001/jama.2013.109309]
81. Curry MP, Forns X, Chung RT, Terrault NA, Brown R, Fenkel JM, Gordon F, O'Leary J, Kuo A, Schiano T, Everson G, Schiff E, Befeler A, Gane E, Saab S, McHutchison JG, Subramanian GM, Symonds WT, Denning J, McNair L, Arterburn S, Svarovskaia E, Moonka D, Afdhal N. Sofosbuvir and ribavirin prevent recurrence of HCV infection after liver transplantation: an open-label study. Gastroenterology 2015; 148: 100-107.e1 [PMID: 25261839]
82. Charlton M, Everson GT, Flamm SL, Kumar P, Landis C, Brown RS, Fried MW, Terrault NA, O'Leary JG, Vargas HE, Kuo A, Schiff E, Sulkowski MS, Gilroy R, Watt KD, Brown K, Kwo P, Pungpapong S, Korenblat KM, Muir AJ, Teperman L, Fontana RJ, Denning J, Arterburn S, Dvory-Sobol H, Brandt-Sarif T, Pang PS, McHutchison JG, Reddy KR, Afdhal N. Ledipasvir and Sofosbuvir Plus Ribavirin for Treatment of HCV Infection in Patients With Advanced Liver Disease. Gastroenterology 2015; 149: 649-659 [PMID: 25985734 DOI: 10.1053/j.gastro.2015.05.010]
83. Casselman JW, Peene PT, Coppens F, Vanneste F. Pneumatocele in a traumatic ruptured lacrimal sac mucocele. Rofo 1989; 150: 106-107 [PMID: 2536488 DOI: 10.7326/M14-1211]
84. Wyles D, Pockros P, Morelli G, Younes Z, Svarovskaia E, Yang JC, Pang PS, Zhu Y, McHutchison JG, Flamm S, Lawitz E. Ledipasvir-sofosbuvir plus ribavirin for patients with genotype 1 hepatitis C virus previously treated in clinical trials of sofosbuvir regimens. Hepatology 2015; 61: 1793-1797 [PMID: 25846014 DOI: 10.1002/hep.27814]
85. Poordad F, Schiff ER, Vierling JM, Landis C, Fontana RJ, Yang R, McPhee F, Hughes E, Noviello S, Swenson ES. Daclatasvir, sofosbuvir, and ribavirin combination for HCV patients with advanced cirhhosis or posttransplant recurrence: phase 3 ALLY-1 study. 50th International Liver Congress. April 22-26 2015; Vienna, Austria
86. AASLD and IDSA Guidelines. Recommendations for Testing Managing and Treating Hepatitis C. Unique patient populations: patients with decompensated cirrhosis. Accessed June 30, 2015. Available from: URL: http://www.hcvguidelines.org/
87. Lens S, Mariño Z, Forns X. Effcacy of new direct acting antivirals in transplant recipients and patients with advanced disease. Dig Liver Dis 2014; 46 Suppl 5: S197-S205 [PMID: 25458782 DOI: 10.1016/j.dld.2014.10.002]
88. Terrault NA. Prophylactic and preemptive therapies for hepatitis C virus-infected patients undergoing liver transplantation. Liver Transpl 2003; 9: S95-S100 [PMID: 14586903 DOI: 10.1053/jlts.2003.50255]
89. Powers KA, Ribeiro RM, Patel K, Pianko S, Nyberg L, Pockros P, Conrad AJ, McHutchison J, Perelson AS. Kinetics of hepatitis C virus reinfection after liver transplantation. Liver Transpl 2006; 12: 207-216 [PMID: 16447184 DOI: 10.1002/lt.20572]
90. Tamura S, Sugawara Y, Yamashiki N, Kaneko J, Kokudo N, Makuuchi M. Pre-emptive antiviral therapy in living donor liver transplantation for hepatitis C: observation based on a single-center experience. Transpl Int 2010; 23: 580-588 [PMID: 20028490 DOI: 10.1111/j.1432-2277.2009.01023.x]
91. Shergill AK, Khalili M, Straley S, Bollinger K, Roberts JP, Ascher NA, Terrault NA. Applicability, tolerability and efficacy of preemptive antiviral therapy in hepatitis C-infected patients undergoing liver transplantation. Am J Transplant 2005; 5: 118-124 [PMID: 15636619 DOI: 10.1111/j.1600-6143.2004.00648.x]
92. Berenguer M, Palau A, Aguilera V, Rayón JM, Juan FS, Prieto M. Clinical benefts of antiviral therapy in patients with recurrent hepatitis C following liver transplantation. Am J Transplant 2008; 8: 679-687 [PMID: 18294165 DOI: 10.1111/j.1600-6143.2007.02126. x]
93. Hanouneh IA, Miller C, Aucejo F, Lopez R, Quinn MK, Zein NN. Recurrent hepatitis C after liver transplantation: on-treatment prediction of response to peginterferon/ribavirin therapy. Liver Transpl 2008; 14: 53-58 [PMID: 18161839 DOI: 10.1002/lt.21312]
94. Biselli M, Andreone P, Gramenzi A, Lorenzini S, Loggi E, Bonvicini F, Cursaro C, Bernardi M. Pegylated interferon plus ribavirin for recurrent Hepatitis C infection after liver transplantation in naïve and non-responder patients on a stable immunosuppressive regimen. Dig Liver Dis 2006; 38: 27-32 [PMID: 16311084 DOI: 10.1016/j.dld.2005.08.009]
95. Fernández I, Meneu JC, Colina F, García I, Muñoz R, Castellano G, Fuertes A, Abradelo M, Lumbreras C, Moreno E, Solís-Herruzo JA. Clinical and histological effcacy of pegylated interferon and ribavirin therapy of recurrent hepatitis C after liver transplantation. Liver Transpl 2006; 12: 1805-1812 [PMID: 17133585 DOI: 10.1002/lt.20883]
96. Oton E, Barcena R, Garcia-Garzon S, Moreno-Zamora A, Moreno A, Garcia-Gonzalez M, Blesa C, Foruny JR, Ruiz P. Pegylated interferon and ribavirin for the recurrence of chronic hepatitis C genotype 1 in transplant patients. Transplant Proc 2005; 37: 3963-3964 [PMID: 16386597 DOI: 10.1016/j.transproceed.2005.1 0.060]
97. Oton E, Barcena R, Moreno-Planas JM, Cuervas-Mons V, Moreno-Zamora A, Barrios C, Garcia-Garzon S, Moreno A, Boullosa-Graña E, Rubio-Gonzalez EE, Garcia-Gonzalez M, Blesa C, Mateos ML. Hepatitis C recurrence after liver transplantation: Viral and histologic response to full-dose PEG-interferon and ribavirin. Am J Transplant 2006; 6: 2348-2355 [PMID: 16869810 DOI: 10.1111/j.1600-6143.2006.01470.x]
98. Castells L, Vargas V, Allende H, Bilbao I, Luis Lázaro J, Margarit C, Esteban R, Guardia J. Combined treatment with pegylated interferon (alpha-2b) and ribavirin in the acute phase of hepatitis C virus recurrence after liver transplantation. J Hepatol 2005; 43: 53-59 [PMID: 15876467 DOI: 10.1016/j.jhep.2005.02.015]
99. Rodriguez-Luna H, Khatib A, Sharma P, De Petris G, Williams JW, Ortiz J, Hansen K, Mulligan D, Moss A, Douglas DD, Balan V, Rakela J, Vargas HE. Treatment of recurrent hepatitis C infection after liver transplantation with combination of pegylated interferon alpha2b and ribavirin: an open-label series. Transplantation 2004; 77: 190-194 [PMID: 14742979 DOI: 10.1097/01. TP.0000100481.14514.BB]
100. Dumortier J, Scoazec JY, Chevallier P, Boillot O. Treatment of recurrent hepatitis C after liver transplantation: a pilot study of peginterferon alfa-2b and ribavirin combination. J Hepatol 2004; 40: 669-674 [PMID: 15030984 DOI: 10.1016/j.jhep.2003.12.015]
101. Mukherjee S, Rogge J, Weaver L, Schafer DF. Pilot study of pegylated interferon alfa-2b and ribavirin for recurrent hepatitis C after liver transplantation. Transplant Proc 2003; 35: 3042-3044 [PMID: 14697974 DOI: 10.1016/j.transproceed.2003.10.083]
102. Wang CS, Ko HH, Yoshida EM, Marra CA, Richardson K. Interferon-based combination anti-viral therapy for hepatitis C virus after liver transplantation: a review and quantitative analysis. Am J Transplant 2006; 6: 1586-1599 [PMID: 16827859 DOI: 10.1111/j.1600-6143.2006.01362.x]
103. Kwo PY, Mantry PS, Coakley E, Te HS, Vargas HE, Brown R, Gordon F, Levitsky J, Terrault NA, Burton JR, Xie W, Setze C, Badri P, Pilot-Matias T, Vilchez RA, Forns X. An interferon-free antiviral regimen for HCV after liver transplantation. N Engl J Med 2014; 371: 2375-2382 [PMID: 25386767 DOI: 10.1056/NEJMoa1408921]
104. Werner CR, Egetemeyr DP, Lauer UM, Nadalin S, Königsrainer A, Malek NP, Berg CP. Feasibility of telaprevir-based triple therapy in liver transplant patients with hepatitis C virus: SVR 24 results. PLoS One 2013; 8: e80528 [PMID: 24265827 DOI: 10.1371/journal.pone.0080528]
105. Kwo P, Ghabril M, Lacerda M, Vinayek R, Tector AJ, Fridell J, Vianna R. Use of telaprevir plus peginterferon/ribavirin for null responders postOL with advanced fibrosis/cholestatic hepatitis C. J Hepatol 2012; 56 Suppl 2: S86 [DOI: 10.1016/S0168-8278(12)60215-3]
106. Burton JR, Everson GT. Initial experience with telaprevir for treating hepatitis C virus in liver recipients: virologic response, safety, and tolerability. Am J Transplant 2012; 12 Suppl 3: 188
107. Coilly A, Roche B, Dumortier J, Leroy V, Botta-Fridlund D, Radenne S, Pageaux GP, Si-Ahmed SN, Guillaud O, Antonini TM, Haïm-Boukobza S, Roque-Afonso AM, Samuel D, Duclos-Vallée JC. Safety and efficacy of protease inhibitors to treat hepatitis C after liver transplantation: a multicenter experience. J Hepatol 2014; 60: 78-86 [PMID: 23994384 DOI: 10.1016/j.jhep.2013.08.018]
108. Pungpapong S, Aqel BA, Koning L, Murphy JL, Henry TM, Ryland KL, Yataco ML, Satyanarayana R, Rosser BG, Vargas HE, Charlton MR, Keaveny AP. Multicenter experience using telaprevir or boceprevir with peginterferon and ribavirin to treat hepatitis C genotype 1 after liver transplantation. Liver Transpl 2013; 19: 690-700 [PMID: 23696372 DOI: 10.1002/lt.23669]
109. Verna EC, Shetty K, Lukose T, Terry N, Mentore K, Olsen SK, Fox AN, Dove LM, Brown RS. High post-transplant virological response in hepatitis C virus infected patients treated with pretransplant protease inhibitor-based triple therapy. Liver Int 2015; 35: 510-517 [PMID: 24905624 DOI: 10.1111/liv.12616]
110. Charlton M, Gane E, Manns MP, Brown RS, Curry MP, Kwo PY, Fontana RJ, Gilroy R, Teperman L, Muir AJ, McHutchison JG, Symonds WT, Brainard D, Kirby B, Dvory-Sobol H, Denning J, Arterburn S, Samuel D, Forns X, Terrault NA. Sofosbuvir and ribavirin for treatment of compensated recurrent hepatitis C virus infection after liver transplantation. Gastroenterology 2015; 148: 108-117 [PMID: 25304641 DOI: 10.1053/j.gastro.2014.10.001]
111. Forns X, Charlton M, Denning J, McHutchison JG, Symonds WT, Brainard D, Brandt-Sarif T, Chang P, Kivett V, Castells L, Prieto M, Fontana RJ, Baumert TF, Coilly A, Londoño MC, Habersetzer F. Sofosbuvir compassionate use program for patients with severe recurrent hepatitis C after liver transplantation. Hepatology 2015; 61: 1485-1494 [PMID: 25557906 DOI: 10.1002/hep.27681]
112. AASLD and IDSA Guidelines. Recommendations for Testing Managing and Treating Hepatitis C. Summary of Recommendations for Patients Who Develop Recurrent HCV Infection Post-Liver Transplantation. Accessed April 3, 2015. Available from: URL: http://www.hcvguidelines.org/
113. Reddy KR, Everson GT, Flamm SL, Denning JM, Arterburn S, Brandt-Sarif T, Pang PS, Dvory-Sobol H, McHutchison GH, Curry MP, Charlton M. Ledipasvir/Sofosbuvir With Ribavirin for the Treatment of HCV in Patients With Post-Transplant Recurrence: Preliminary Results of a Prospective, Multicenter Study. 65th Annual Meeting of the American Association for the Study of Liver Diseases (AASLD), November 7-11, 2014; Boston, United States
114. Gane EJ, Hyland RH, An D, Svarovskaia E, Pang PS, Brainard D, Stedman CA. Effcacy of Ledipasvir and Sofosbuvir, With or Without Ribavirin, for 12 Weeks in Patients With HCV Genotype 3 or 6 Infection. Gastroenterology 2015; Epub ahead of print [PMID: 26261007 DOI: 10.1053/j.gastro.2015.07.063]
115. Pellicelli AM, Montalbano M, Lionetti R, Durand C, Ferenci P, D'Offizi G, Knop V, Telese A, Lenci I, Andreoli A, Zeuzem S, Angelico M. Sofosbuvir plus daclatasvir for post-transplant recurrent hepatitis C: potent antiviral activity but no clinical beneft if treatment is given late. Dig Liver Dis 2014; 46: 923-927 [PMID: 24997638 DOI: 10.1016/j.dld.2014.06.004]
116. Fontana R. High efficacy and favorable safety profile of Daclatasvir based all oral antiviral therapy in liver Transplant recipients with severe recurrent HCV. 65th Annual Meeting of the American Association for the Study of Liver Diseases (AASLD), November 7-11, 2014; Boston, United States
117. Mantry P, Kwo PY, Coakley E, Te HS, Vargas HE, Brown RS, Gordon FD, Levitsky J, Terrault N, Burton JR, Xie W, Setze C, Badri P, Vilchez RA, Forns X. High Sustained Virologic Response Rates in Liver Transplant Recipients With Recurrent HCV Genotype 1 Infection Receiving ABT-450/r/Ombitasvir Dasabuvir Plus Ribavirin. 65th Annual Meeting of the American Association for the Study of Liver diseases, November 7-11, 2014, Boston, United States
118. Gutierrez JA, Carrion AF, Avalos D, O'Brien C, Martin P, Bhamidimarri KR, Peyton A. Sofosbuvir and simeprevir for treatment of hepatitis C virus infection in liver transplant recipients. Liver Transpl 2015; 21: 823-830 [PMID: 25825070 DOI: 10.1002/lt.24126]
119. Pungpapong S, Aqel B, Leise M, Werner KT, Murphy JL, Henry TM, Ryland K, Chervenak AE, Watt KD, Vargas HE, Keaveny AP. Multicenter experience using simeprevir and sofosbuvir with or without ribavirin to treat hepatitis C genotype 1 after liver transplant. Hepatology 2015; 61: 1880-1886 [PMID: 25722203 DOI: 10.1002/hep.27770]
120. Brown RS, Reddy KRJ, O'Leary JG, Kuo A, Morelli G, Stravitz RT. Safety and effcacy of new DAA-based therapy for hepatitis C post-transplant: interval results from the HCV-TARGET longitudinal, observational study. Hepatology 2014; 60: 1269A
121. Weber R, Sabin CA, Friis-Møller N, Reiss P, El-Sadr WM, Kirk O, Dabis F, Law MG, Pradier C, De Wit S, Akerlund B, Calvo G, Monforte Ad, Rickenbach M, Ledergerber B, Phillips AN, Lundgren JD. Liver-related deaths in persons infected with the human immunodeficiency virus: the D: A: D study. Arch Intern Med 2006; 166: 1632-1641 [PMID: 16908797 DOI: 10.1001/archinte.166.15.1632]
122. Marcellin P, Pequignot F, Delarocque-Astagneau E, Zarski JP, Ganne N, Hillon P, Antona D, Bovet M, Mechain M, Asselah T, Desenclos JC, Jougla E. Mortality related to chronic hepatitis B and chronic hepatitis C in France: evidence for the role of HIV coinfection and alcohol consumption. J Hepatol 2008; 48: 200-207 [PMID: 18086507 DOI: 10.1016/j.jhep.2007.09.010]
123. Moreno A, Cervera C, Fortún J, Blanes M, Montejo E, Abradelo M, Len O, Rafecas A, Martín-Davila P, Torre-Cisneros J, Salcedo M, Cordero E, Lozano R, Pérez I, Rimola A, Miró JM. Epidemiology and outcome of infections in human immunodeficiency virus/hepatitis C virus-coinfected liver transplant recipients: a FIPSE/GESIDA prospective cohort study. Liver Transpl 2012; 18: 70-81 [PMID: 21898772 DOI: 10.1002/lt.22431]
124. Sawinski D, Forde KA, Eddinger K, Troxel AB, Blumberg E, Tebas P, Abt PL, Bloom RD. Superior outcomes in HIV-positive kidney transplant patients compared with HCV-infected or HIV/HCV-coinfected recipients. Kidney Int 2015; 88: 341-349 [PMID: 25807035 DOI: 10.1038/ki.2015.74]
125. Norris S, Taylor C, Muiesan P, Portmann BC, Knisely AS, Bowles M, Rela M, Heaton N, O'Grady JG. Outcomes of liver transplantation in HIV-infected individuals: the impact of HCV and HBV infection. Liver Transpl 2004; 10: 1271-1278 [PMID: 15376307 DOI: 10.1002/lt.20233]
126. Righi E, Londero A, Pea F, Bonora S, Nasta P, Della Siega P, Delle Foglie P, Villa G, Giglio O, Dal Zoppo S, Baccarani U, Bassetti M. Antiretroviral blood levels in HIV/HCV-coinfected patients with cirrhosis after liver transplant: a report of three cases. Transpl Infect Dis 2015; 17: 147-153 [PMID: 25620392 DOI: 10.1111/tid.12339]
127. Wyles DL, Gerber JG. Antiretroviral drug pharmacokinetics in hepatitis with hepatic dysfunction. Clin Infect Dis 2005; 40: 174-181 [PMID: 15614709 DOI: 10.1086/426021]
128. Righi E, Beltrame A, Bassetti M, Lindstrom V, Mazzarello G, Dentone C, Di Biagio A, Ratto S, Viscoli C. Therapeutical aspects and outcome of HIV/HCV coinfected patients treated with pegylated interferon plus ribavirin in an Italian cohort. Infection 2008; 36: 358-361 [PMID: 18642111 DOI: 10.1007/s15010-008-7319-5]
129. Castells L, Rimola A, Manzardo C, Valdivieso A, Montero JL, Barcena R, Abradelo M, Xiol X, Aguilera V, Salcedo M, Rodriguez M, Bernal C, Suarez F, Antela A, Olivares S, Del Campo S, Laguno M, Fernandez JR, de la Rosa G, Agüero F, Perez I, González-García J, Esteban-Mur JI, Miro JM. Pegylated interferon plus ribavirin in HIV-infected patients with recurrent hepatitis C after liver transplantation: a prospective cohort study. J Hepatol 2015; 62: 92-100 [PMID: 25127748 DOI: 10.1016/j.jhep.2014.07.034]
130. Baccarani U, Righi E, Adani GL, Lorenzin D, Pasqualucci A, Bassetti M, Risaliti A. Pros and cons of liver transplantation in human immunodeficiency virus infected recipients. World J Gastroenterol 2014; 20: 5353-5362 [PMID: 24833865 DOI: 10.3748/wjg.v20.i18.5353]
131. Duclos-Vallée JC, Féray C, Sebagh M, Teicher E, Roque-Afonso AM, Roche B, Azoulay D, Adam R, Bismuth H, Castaing D, Vittecoq D, Samuel D. Survival and recurrence of hepatitis C after liver transplantation in patients coinfected with human immunodefciency virus and hepatitis C virus. Hepatology 2008; 47: 407-417 [PMID: 18098295 DOI: 10.1002/hep.21990]
132. Antonini TM, Furlan V, Teicher E, Haim-Boukobza S, Sebagh M, Coilly A, Bonhomme-Faivre L, Roque-Afonso AM, Vittecoq D, Samuel D, Taburet AM, Duclos-Vallée JC. Therapy with boceprevir or telaprevir in HIV/hepatitis C virus co-infected patients to treat recurrence of hepatitis C virus infection after liver transplantation. AIDS 2015; 29: 53-58 [PMID: 25387314 DOI: 10.1097/QAD.0000000000000516]
133. Moreno A, Perez-Elias MJ, Barcena R, Quereda C, Casado JL, Dronda F, Mateos ML, Diaz A, Moreno S. Safety and Effcacy of IFN-free, Sofosbuvir/RBV Therapy in HIV/HCV Liver Transplanted Patients. 21st Conference on Retroviruses and Opportunistic Infections (CROI) March 3-6, 2014, Boston, United States
134. Rockstroh JK, Puoti M, Rodriguez-Torres M, Dieterich D, Gaggar A, Ni L, Massetto B, Svarovskaia ES, Brainard DM, Subramanian M, McHutchison JG, Naggie S, Orkin C, Molina JM, Sulkowski MS. Sofosbuvir and Ribavirin therapy for the Treatment of HIV/HCV coinfected patients with HCV GT1-4 Infection: The PHOTON-1 and-2 Trials. Presented at: 65th Annual Meeting of the American Association for the Study of Liver diseases, November 7-11, 2014, Boston, United States
135. Osinusi A, Townsend K, Kohli A, Nelson A, Seamon C, Meissner EG, Bon D, Silk R, Gross C, Price A, Sajadi M, Sidharthan S, Sims Z, Herrmann E, Hogan J, Teferi G, Talwani R, Proschan M, Jenkins V, Kleiner DE, Wood BJ, Subramanian GM, Pang PS, McHutchison JG, Polis MA, Fauci AS, Masur H, Kottilil S. Virologic response following combined ledipasvir and sofosbuvir administration in patients with HCV genotype 1 and HIV co-infection. JAMA 2015; 313: 1232-1239 [PMID: 25706232 DOI: 10.1001/jama.2015.1373]
136. Naggie S, Cooper C, Saag M, Yang J. Ledipasvir/sofosbuvir for 12 wk in patients coinfected with HCV and HIV-1. Presented at: 22nd Conference on Retroviruses and Opportunistic Infections (CROI) 2015. February 23-26, 2015; Seattle, United States
137. Sulkowski MS, Eron JJ, Wyles D, Trinh R, Lalezari J, Wang C, Slim J, Bhatti L, Gathe J, Ruane PJ, Elion R, Bredeek F, Brennan R, Blick G, Khatri A, Gibbons K, Hu YB, Fredrick L, Schnell G, Pilot-Matias T, Tripathi R, Da Silva-Tillmann B, McGovern B, Campbell AL, Podsadecki T. Ombitasvir, paritaprevir co-dosed with ritonavir, dasabuvir, and ribavirin for hepatitis C in patients co-infected with HIV-1: a randomized trial. JAMA 2015; 313: 1223-1231 [PMID: 25706092 DOI: 10.1001/jama.2015.1328]
138. Sulkowski M, Hezode C, Gerstoft J, Vierling JM, Mallolas J, Pol S, Kugelmas M, Murillo A, Weis N, Nahass R, Shibolet O, Serfaty L, Bourliere M, DeJesus E, Zuckerman E, Dutko F, Shaughnessy M, Hwang P, Howe AY, Wahl J, Robertson M, Barr E, Haber B. Effcacy and safety of 8 weeks versus 12 weeks of treatment with grazoprevir (MK-5172) and elbasvir (MK-8742) with or without ribavirin in patients with hepatitis C virus genotype 1 mono-infection and HIV/hepatitis C virus co-infection (C-WORTHY): a randomised, open-label phase 2 trial. Lancet 2015; 385: 1087-1097 [PMID: 25467560 DOI: 10.1016/S0140-6736(14)61793-1]
139. Del Bello DP, Bichoupan K, Yalamanchili R. Real-world data on HIV positive patients with HCV genotype 1, 2 and 3 on sofosbuvir-and simeprevir containing regimens. Presented at: 65th Annual Meeting of the American Association for the Study of Liver Diseases (AASLD). November 7-1, 2014, Boston, United States
140. Wyles D, Ruane P, Sulkowski, Dieterich D. Daclatasvir in combination with sofosbuvir for HIV/HCV coinfection: ALLY-2 study. 22nd Conference on Retroviruses and Opportunistic Infections (CROI), February 23-26, 2015; Seattle, United States
141. Burgess S, Partovi N, Yoshida EM, Erb SR, Azalgara VM, Hussaini T. Drug Interactions With Direct-Acting Antivirals for Hepatitis C: Implications for HIV and Transplant Patients. Ann Pharmacother 2015; 49: 674-687 [PMID: 25770114 DOI: 10.1177/1060028015576180]
142. Miro JM, Stock P, Teicher E, Duclos-Vallée JC, Terrault N, Rimola A. Outcome and management of HCV/HIV coinfection pre-and post-liver transplantation. A 2015 update. J Hepatol 2015; 62: 701-711 [PMID: 25450714 DOI: 10.1016/j.jhep.2014.10.032]
143. Jacobson IM, Gordon SC, Kowdley KV, Yoshida EM, Rodriguez-Torres M, Sulkowski MS, Shiffman ML, Lawitz E, Everson G, Bennett M, Schiff E, Al-Assi MT, Subramanian GM, An D, Lin M, McNally J, Brainard D, Symonds WT, McHutchison JG, Patel K, Feld J, Pianko S, Nelson DR. Sofosbuvir for hepatitis C genotype 2 or 3 in patients without treatment options. N Engl J Med 2013; 368: 1867-1877 [PMID: 23607593 DOI: 10.1056/NEJMoa1214854]
144. Zeuzem S, Dusheiko GM, Salupere R, Mangia A, Flisiak R, Hyland RH, Illeperuma A, Svarovskaia E, Brainard DM, Symonds WT, Subramanian GM, McHutchison JG, Weiland O, Reesink HW, Ferenci P, Hézode C, Esteban R. Sofosbuvir and ribavirin in HCV genotypes 2 and 3. N Engl J Med 2014; 370: 1993-2001 [PMID: 24795201 DOI: 10.1056/NEJMoa1316145]
145. Forns X, García-Retortillo M, Serrano T, Feliu A, Suarez F, de la Mata M, García-Valdecasas JC, Navasa M, Rimola A, Rodés J. Antiviral therapy of patients with decompensated cirrhosis to prevent recurrence of hepatitis C after liver transplantation. J Hepatol 2003; 39: 389-396 [PMID: 12927925 DOI: 10.1016/S0168-8278(03)00310-6]
146. Ueda Y, Takada Y, Marusawa H, Egawa H, Uemoto S, Chiba T. Individualized extension of pegylated interferon plus ribavirin therapy for recurrent hepatitis C genotype 1b after living-donor liver transplantation. Transplantation 2010; 90: 661-665 [PMID: 20110853 DOI: 10.1097/TP.0b013e3181d2bfca]